Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | CNR2 | P34972 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.44 |
| ▸ | LMNA | P02545 | 4/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | AR | P10275 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | TACR1 | P25103 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL435727 | 0.85 | LMNA (0.48) | GAANPSR1ALDH1A1LMNAHTT | |
| SCHEMBL8904963 | 0.85 | LMNA (0.48) | GAANPSR1ALDH1A1LMNAHTT | |
| SCHEMBL15399429 | 0.79 | MEN1 (0.40) | ALDH1A1LMNAKDM4EMAPTTSHR | |
| SCHEMBL1336544 | 0.74 | LMNA (0.45) | GAANPSR1ALDH1A1LMNAHTT | |
| SCHEMBL5739149 | 0.72 | ALDH1A1 (0.66) | GAANPSR1CNR2ALDH1A1LMNA | |
| SCHEMBL11627077 | 0.72 | KCNA5 (0.56) | ALDH1A1KDM4EMAPTHTTSMN1; SMN2 | |
| SCHEMBL9650536 | 0.71 | CYP2B6 (0.46) | ALDH1A1LMNAKDM4ETSHRSMN1; SMN2 | |
| Fluoride SCHEMBL30661872 | 0.71 | TSHR (0.64) | GAANPSR1ALDH1A1MAPTTDP1 | |
| Benzene SCHEMBL8568955 | 0.71 | TSHR (0.67) | GAANPSR1ALDH1A1LMNAMAPT | |
| SCHEMBL5280949 | 0.70 | KCNN4 (0.48) | NPSR1ALDH1A1LMNAMAPTHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070037800-A1 | Method of treating neurological disorders using clotrimazole and derivatives thereof | ENVIVO PHARMACEUTICALS, INC. | 2007-02-15 | — | — | US | disclosed |
| WO-2007002497-A1 | METHOD OF TREATING NEUROLOGICAL DISORDERS USING CLOTRIMAZOLE AND DERIVATIVES THEREOF | ENVIVO PHARMACEUTICALS, INC. (US) | 2007-01-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070037800-A1 | Method of treating neurological disorders using clotrimazole and derivatives thereof | HTT, HYPK, GRIK3 | GAA 109/4885NPSR1 1585/4885CNR2 549/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.